Gastric/Gastroesophageal Junction Adenocarcinoma Clinical Trials in Jinan, Shandong
3 recruitingJinan, Shandong, China
Showing 1–3 of 3 trials
Recruiting
Phase 2
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
HER2-negativeLow PD-L1 ExpressingUnresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University77 enrolled29 locationsNCT06932068
Recruiting
Phase 2
A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Shandong Provincial Hospital96 enrolled1 locationNCT06829797
Recruiting
Phase 2
Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Shandong Provincial Hospital32 enrolled1 locationNCT06766578